Telix to Present at Jefferies London Healthcare Conference 2022
MELBOURNE, Australia, Nov. 11, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company), a commercial-stage biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals, advises that DrChristian Behrenbruch,...
Telix Announces Positive Topline Results of ZIRCON Phase III Kidney Cancer Imaging Study
Summary of Study Outcomes * ZIRCON Phase III study of Telix's investigational imaging agent TLX250-CDx in clear cell renal cell carcinoma (ccRCC) has met all of its primary and secondary endpoints * The study delivered co-primary endpoints of 86% sensitivity and 87% specificity and 93% posit...
Telix Recognised as Company of the Year at AusBiotech and Johnson & Johnson Innovation Industry Excellence Awards 2022
MELBOURNE, Australia, Oct. 27, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) is today pleased to announce that it has been awarded Australian Company of the Year in the 2022 AusBiotech and Johnson & Johnson Innovation Industry Excellence Awards, held today at t...
Telix and UniQuest to Collaborate on Radiolabelled Immune Targeting Peptide
MELBOURNE, Australia, Oct. 27, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces a collaboration with UniQuest Pty Ltd (UniQuest), the commercialisation company of TheUniversity of Queensland (UQ), to develop a radiolabelled molecule targeting an im...
Telix Reports Third Quarter 2022 Financial Results
MELBOURNE, Australia, Oct. 20, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today issues its Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarter ended30 September 2022 (Q3 2022). All figures are in AUD$ unless otherwise...
TLX250-CDx Indication Expansion: Preliminary Data Presented at EANM
* OPALESCENCE Phase II feasibility study of TLX250-CDx in patients with triple-negative breast cancer – early results suggest potential to detect carbonic anhydrase IX (CAIX) expression, theranostic potential in this difficult to treat disease. * PERTINENCE Early Phase I feasibility study of ...
Telix Partnership Expands GE Healthcare Immuno-Diagnostics Offering to the Global Clinical Research Market
* New agreement adds two Telix investigational PET imaging radiotracers to GE Healthcare's immuno-diagnostic portfolio, to enable patient selection and monitoring in immunotherapy trials * Telix tracers evaluate levels of carbonic anhydrase IX and lactate in tumours to inform and improve ther...
Chinese NMPA Approves Pivotal Phase III Study of TLX591-CDx for Prostate Cancer Imaging
MELBOURNE, Australia, Oct. 17, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the Chinese National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has approved an investigational new drug (IND) application to commence...
Health Canada Approves Illuccix® for Prostate Cancer Imaging
MELBOURNE, Australia, Oct. 14, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) announces that Health Canada has approved Illuccix® [kit for the preparation of gallium (68Ga) gozetotide injection] for use in staging and re-staging intermediate and high-risk prost...
First Patient in New Zealand Dosed with Illuccix® - Telix's Prostate Cancer Imaging Agent
MELBOURNE, Australia, Sept. 30, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces the first commercial dose inNew Zealand of its prostate cancer imaging agent, Illuccix® (Kit for Preparation of Ga-68 Glu-urea-Lys(ahx)-hbed-CC Injection), also known ...
Chinese NMPA Approves Study of Telix Kidney Cancer Imaging Candidate
MELBOURNE, Australia, Sept. 28, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the Chinese National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has approved a pivotal Phase III registration study that will bridge ...
First Patient in Australia Dosed with Illuccix® - Telix's Approved Prostate Cancer Imaging Agent
MELBOURNE, Australia, Sept. 28, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces the first commercial dose inAustralia of its prostate cancer imaging agent, Illuccix® (Kit for Preparation of Ga-68 Glu-urea-Lys(ahx)-hbed-CC Injection), also known as...
First Patient Enrolled in ProstACT TARGET Study
MELBOURNE, Australia, Sept. 27, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) and GenesisCare, the largest provider of integrated cancer care inAustralia, today announce that a first patient has been enrolled in the Phase II ProstACT TARGET study of Telix's pro...
Final IPAX-1 Study Data Confirms Safety and Tolerability Profile for TLX101, Preliminary Efficacy Data
MELBOURNE, Australia, Sept. 21, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today reports the final results from the IPAX-1 Ph I/II study of TLX101 therapy (4-L-[131I] iodo-phenylalanine, or 131 I-IPA) in combination with external beam radiation therapy (EBRT)...
Targeted Alpha Therapy Candidate: Bladder Cancer Study Completes Enrolment
MELBOURNE, Australia and NANTES, France, Aug. 24, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) and Nantes-based ATONCO S.A.S. ('ATONCO') today announced that the final patient has been dosed in a Phase I study of TLX250-CDx in patients with non-muscle invasive...
Telix and University of Queensland-led Consortium Awarded $5M Australian Research Council (ARC) Grant
MELBOURNE, Australia, Aug. 8, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has been jointly awarded a$4.8 million Australian Research Council (ARC) grant to establish a new Industrial Transformation Research Program (ITRP) Hub as part o...
Telix APAC Report: Regulatory Progress for Prostate and Kidney Cancer Imaging
MELBOURNE, Australia, Aug. 2, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today reports on regulatory progress for the Company's core prostate and kidney cancer imaging programs in theAsia Pacific (APAC) Operating Region, including progress in the major marke...
BAMF Health and Telix complete first total-body PET scans with Illuccix for prostate cancer imaging
Telix and BAMF Health use Illuccix® (kit for the preparation of Gallium Ga 68 gozetotide injection) for the first time with uEXPLORER® total-body PET scanner for prostate cancer imaging GRAND RAPIDS, Mich. and INDIANAPOLIS, July 27, 2022 /PRNewswire/ -- The PSMA-PET[1] imaging agent Illuccix® fr...
Telix Reports Second Quarter 2022 Financial Results
MELBOURNE, Australia, July 21, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today issues its Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarter ended30 June 2022. All figures are in AUD$ unless otherwise stated. All fi...
ZIRCON Phase III Kidney Cancer Imaging Study Completes Enrolment
MELBOURNE, Australia, July 11, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has dosed the final patient and completed recruitment into the Phase III pivotal study ZIRCON (Zirconium in Renal Cancer Oncology, NCT03849118) of its investiga...
